[ad_1]
One of the founders of the German biotechnology company BioNTech, which produced the vaccine developed against Kovid-19 and declared to be 90 percent successful. Dr. Uğur Şahin made an important statement.
“REDUCE THE SPREAD OF PANDEM BY 50 PERCENT”
Speaking on the Andrew Marr Show on the BBC, inahin stated that he is confident that human-to-human transmission with such a high-impact vaccine will decrease not perhaps 90 percent but 50 percent, and that even this will significantly reduce the spread of the pandemic.
“300 MILLION DOSES WILL BE DISTRIBUTED UNTIL APRIL”
Stating that if all goes well, the vaccine will begin shipping late this winter or early next year, Şahin said his goal is to distribute at least 300 million doses worldwide by April.
“NEXT WINTER WE CAN GO TO NORMAL”
Emphasizing that he can return to normal life next winter, Şahin noted that it is important to complete the entire vaccination program before next fall.
Noting that the summer months will also help fight the virus by decreasing infection rates, Şahin said a high level of vaccination needs to be achieved in the fall of next year.
“THE VACCINE HAS NO SERIOUS SIDE EFFECTS”
Noting that the side effects of the vaccine were pain that lasted a few days at the site where the vaccine was given and a mild fever that lasted a few days in some subjects, Şahin said that they found no serious side effect that stopped or paused the study.
“THE VACCINE IS MORE THAN 90 PERCENT EFFECTIVE”
The American pharmaceutical company Pfizer and the Turkish scientist Prof. Dr. The possible vaccine developed by the German biotechnology company BioNTech, of which Uğur Şahin was a founding partner, was reported to be more than 90 percent effective against the virus. It was announced that the candidate vaccine BNT162b1 has been tested in 43,538 people in 6 countries, and there have been no serious safety issues in the trials so far.
1.3 BILLION DOSES OF VACCINES ARE PRODUCED IN ONE YEAR
As countries around the world compete to sign contracts for millions of doses of vaccines, BioNTech previously announced plans to produce 100 million more vaccines globally by the end of 2020 and about 1.3 billion more doses by the end of 2021. Pfizer and BioNTech signed a preliminary agreement with the US, EU, UK, Canada and Japan for the supply of the vaccine.
CLICK FOR BREAKING NEWS FROM THE CORONAVIRUS!
